Physician profile
Benjamin Maughan
NPI 1255656120
$142,449.04
in general payments reported to CMS, 2019-2025
24 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $6,923 · 2021: $25K · 2022: $25K · 2023: $21K · 2024: $24K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,340 · Travel and Lodging: $5,001 · Food and Beverage: $3,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,473.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,340.00 |
| Travel and Lodging | $5,001.25 |
| Food and Beverage | $3,701.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47,619.66 | 2019-2025 | |
| Pfizer INC. | $19,339.09 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $10,094.51 | 2019-2024 | |
| Eisai INC. | $9,918.78 | 2023-2025 | |
| Exelixis INC. | $7,421.88 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $6,158.87 | 2019-2022 | |
| Genzyme Corporation | $6,132.69 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $5,541.59 | 2019-2021 | |
| Janssen Global Services, LLC | $5,500.00 | 2024 | Erleada |
| Merck Sharp & Dohme LLC | $5,415.00 | 2021-2024 | |
| Astellas Pharma Global Development | $5,282.86 | 2019-2024 | Xtandi |
| Eli Lilly and Company | $4,800.00 | 2022 | |
| Astellas Pharma US INC | $3,228.58 | 2021 | |
| Eisai Co., LTD. | $2,205.00 | 2025 | |
| Aveo Pharmaceuticals, INC. | $2,189.33 | 2021-2025 | Fotivda |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $968.11 | 2023 | Illuccix |
| Emd Serono, INC. | $255.00 | 2020 | |
| Genentech USA, INC. | $149.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $93.42 | 2024 | Lynparza |
| Dendreon Pharmaceuticals LLC | $53.55 | 2022 | |
| Myovant Sciences INC. | $46.24 | 2022 | |
| Genentech, INC. | $35.54 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Maughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.